{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:38Z","timestamp":1793234318260,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cmi.2024.12.032","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T02:41:33Z","timestamp":1735526493000},"page":"731-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fungal infection in patients treated with Bruton tyrosine kinase inhibitor\u2014from epidemiology to clinical outcome: a systematic review"],"prefix":"10.1016","volume":"31","author":[{"given":"Charles","family":"Gibert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Blaize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fekkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.12.032_bib1","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/OTT.S249586","article-title":"Ibrutinib in chronic lymphocytic leukemia: clinical applications, drug resistance, and prospects","volume":"13","author":"Zhou","year":"2020","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.cmi.2024.12.032_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clml.2018.02.003","article-title":"Chronic lymphocytic leukemia: a review of front-line treatment options, with a focus on elderly CLL patients","volume":"18","author":"O\u2019Reilly","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2024.12.032_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.12.032_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.critrevonc.2007.04.008","article-title":"Chronic lymphocytic leukemia","volume":"64","author":"Ghia","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cmi.2024.12.032_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A\u00a0new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2024.12.032_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.12.032_bib7","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.5045\/br.2020.S012","article-title":"Recent advances in chronic lymphocytic leukemia therapy","volume":"55","author":"Uhm","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.cmi.2024.12.032_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ajhp\/zxad210","article-title":"Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies","volume":"81","author":"Tham","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.cmi.2024.12.032_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152611794407755","article-title":"Epidemiology and management of infectious complications of contemporary management of chronic leukemias","volume":"11","author":"Young","year":"2011","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.cmi.2024.12.032_bib10","first-page":"217","article-title":"Relationship between immunoglobulin levels, lymphocyte subpopulations and Rai staging in patients with B-CLL","volume":"69","author":"Whelan","year":"1983","journal-title":"Acta Haematol"},{"key":"10.1016\/j.cmi.2024.12.032_bib11","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2024.12.032_bib12","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/HS9.0000000000000175","article-title":"From biology to therapy: the CLL success story","volume":"3","author":"Yosifov","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.cmi.2024.12.032_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700369","article-title":"Targeting Bruton\u2019s tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: preclinical and clinical developments of small molecule inhibitors","volume":"351","author":"Zhang","year":"2018","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.cmi.2024.12.032_bib14","first-page":"66","article-title":"Imbruvica (Ibrutinib), First-in-class Bruton\u2019s tyrosine kinase inhibitor, receives expanded indications for patients with relapsed chronic lymphocytic leukemia","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.cmi.2024.12.032_bib15","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.12.032_bib16","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern","volume":"131","author":"Rogers","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.12.032_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12281-019-00343-9","article-title":"Fungal infections with ibrutinib and other small-molecule kinase inhibitors","volume":"13","author":"Zarakas","year":"2019","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.cmi.2024.12.032_bib18","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.cmi.2024.12.032_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.032_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3324\/haematol.2019.219220","article-title":"Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus","volume":"105","author":"Blez","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.12.032_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107000","article-title":"Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with Acalabrutinib-findings from three cases","volume":"142","author":"Blaize","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.032_bib22","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK inhibition impairs the innate response against fungal infection in patients with chronic lymphocytic leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2024.12.032_bib23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.12.032_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cmi.2024.12.032_bib25","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.mayocp.2023.05.017","article-title":"Invasive central nervous system aspergillosis in a patient receiving long-term acalabrutinib therapy","volume":"98","author":"Tawfiq","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2024.12.032_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.7564","article-title":"Disseminated fungal infection in a patient receiving zanubrutinib","volume":"11","author":"Walsh","year":"2023","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.cmi.2024.12.032_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176142","article-title":"BTK drives neutrophil activation for sterilizing antifungal immunity","volume":"134","author":"Desai","year":"2024","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cmi.2024.12.032_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae115","article-title":"Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a case-control propensity score\u2013matched analysis","volume":"11","author":"Agudelo Higuita","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.032_bib29","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.12.032_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/myc.13676","article-title":"Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: a nationwide population-based cohort study","volume":"67","author":"Allouchery","year":"2024","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2024.12.032_bib31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/ciab1026","article-title":"Incidence of invasive fungal infections in patients initiating ibrutinib and other small molecule kinase inhibitors-United States, July 2016-June 2019","volume":"75","author":"Gold","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.032_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.12.032_bib33","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.12.032_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/17474086.2022.2074393","article-title":"BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?","volume":"15","author":"Desikan","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.cmi.2024.12.032_bib35","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/ijms25042208","article-title":"Bruton\u2019s tyrosine kinase inhibitors: recent updates","volume":"25","author":"Fares","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2024.12.032_bib36","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2024.12.032_bib37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/14656566.2024.2390121","article-title":"Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: latest research findings and systematic analysis","volume":"25","author":"Dasanu","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cmi.2024.12.032_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets\u2014beyond B lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.cmi.2024.12.032_bib39","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.12.032_bib40","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2024.12.032_bib41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0035-3787(04)70997-2","article-title":"[Cerebral aspergillosis]","volume":"160","author":"Tattevin","year":"2004","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.cmi.2024.12.032_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.12.032_bib43","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24006396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24006396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:13:40Z","timestamp":1777641220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24006396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1198743X24006396"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.12.032","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fungal infection in patients treated with Bruton tyrosine kinase inhibitor\u2014from epidemiology to clinical outcome: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}